Morgan Stanley (CCCC) discloses 9.3% C4 Therapeutics stake via Schedule 13G/A

Rhea-AI Filing Summary

Morgan Stanley and Morgan Stanley & Co. LLC report a significant passive stake in C4 Therapeutics, Inc. common stock. They beneficially own 8,974,191 shares, representing 9.3% of the class as of 12/31/2025, with all voting and dispositive power held on a shared basis.

The firms state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of C4 Therapeutics.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

C4 Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

12529R107

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 12529R107

1

Names of Reporting Persons

Morgan Stanley

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,973,891.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,974,191.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,974,191.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.3 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP No. 12529R107

1

Names of Reporting Persons

Morgan Stanley & Co. LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,897,942.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,897,942.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,897,942.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.2 %

12

Type of Reporting Person (See Instructions)

BD, CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: C4 Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 490 ARSENAL WAY, SUITE 120, WATERTOWN, MA, 02472
Item 2.
(a)	Name of person filing: 1: Morgan Stanley 2: Morgan Stanley & Co. LLC
(b)	Address or principal business office or, if none, residence: 1: 1585 Broadway, New York, NY 10036 ;2: 1585 Broadway, New York, NY 10036
(c)	Citizenship: 1: Delaware 2: Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 12529R107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: 9.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99.2
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Morgan Stanley

Signature:	Chris O'Hara
Name/Title:	Authorized Signatory, Morgan Stanley
Date:	02/11/2026

Morgan Stanley & Co. LLC

Signature:	Chris O'Hara
Name/Title:	Authorized Signatory, Morgan Stanley & Co. LLC
Date:	02/11/2026

Exhibit Information

EXHIBIT NO. EXHIBITS ------------------ ------------------------------------ 99.1 Joint Filing Agreement 99.2 Item 7 Information * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).

FAQ

What ownership stake does Morgan Stanley report in C4 Therapeutics (CCCC)?

Morgan Stanley reports beneficial ownership of 8,974,191 shares of C4 Therapeutics common stock, representing 9.3% of the outstanding class as of 12/31/2025. All voting and dispositive power over these shares is described as shared rather than sole.

How many C4 Therapeutics (CCCC) shares does Morgan Stanley & Co. LLC hold?

Morgan Stanley & Co. LLC reports beneficial ownership of 8,897,942 shares of C4 Therapeutics common stock, representing 9.2% of the class. These shares are held with shared voting and shared dispositive power, and no sole voting or dispositive authority is reported.

Is Morgan Stanley’s C4 Therapeutics (CCCC) position a control-seeking stake?

The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control of C4 Therapeutics, characterizing the position as a passive investment under Schedule 13G rules.

What type of reporting persons are listed for Morgan Stanley in the C4 Therapeutics (CCCC) filing?

Morgan Stanley is classified as HC (a parent holding company or control person), while Morgan Stanley & Co. LLC is classified as BD (a registered broker-dealer). Both entities are organized in Delaware and share the same principal business address in New York.

What voting and dispositive powers are disclosed over C4 Therapeutics (CCCC) shares?

The report shows 0 shares with sole voting or sole dispositive power. Morgan Stanley has 8,973,891 shares with shared voting power and 8,974,191 shares with shared dispositive power, indicating decisions over these holdings are made on a shared basis.